Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.2K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.6K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ingested (oral) adrenocorticotropic hormone (ACTH) inhibits interleukin-17 in the central nervous system after adoptive transfer of T helper (Th)1/Th17 T cells in the mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis.

Journal of the neurological sciences·2023
Same author

The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica.

Autoimmunity reviews·2022
Same author

Ingested (Oral) Adrenocorticotropic Hormone Inhibits IL-17 in the Central Nervous System in the Mouse Model of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.

ImmunoHorizons·2022
Same author

Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer's Disease.

Journal of Alzheimer's disease : JAD·2021
Same author

A proposal: How to study pro-myelinating proteins in MS.

Autoimmunity reviews·2021
Same author

Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects.

Multiple sclerosis and related disorders·2020
Same journal

Adjunctive gypenosides for acute optic neuritis: A prematurely terminated randomized, double-blind, placebo-controlled pilot trial in a cohort with frequent AQP4-IgG positivity.

Multiple sclerosis and related disorders·2026
Same journal

Genetic and molecular architecture of multiple sclerosis in gulf cooperation council populations: A scoping review and regional precision-neurology perspective.

Multiple sclerosis and related disorders·2026
Same journal

Rising burden and future projections of multiple sclerosis in East Asia: Findings from the global burden of disease study 2021.

Multiple sclerosis and related disorders·2026
Same journal

Impact of pain subtypes on disability and quality of life in multiple sclerosis: Neuropathic pain demonstrates the strongest association.

Multiple sclerosis and related disorders·2026
Same journal

Bridging to low-dose corticosteroids after satralizumab discontinuation in unplanned pregnancy: Two cases of AQP4-positive NMOSD.

Multiple sclerosis and related disorders·2026
Same journal

Does laughter yoga really improve fatigue, sleep quality and psychological wellbeing in people living with MS?

Multiple sclerosis and related disorders·2026
See all related articles

Related Experiment Video

Updated: Nov 5, 2025

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.7K

Immune reconstitution therapy in NMOSD.

Staley A Brod1

  • 1Department of Neurology, Medical College of Wisconsin, Medical College of Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI 53226, United States.

Multiple Sclerosis and Related Disorders
|May 16, 2021
PubMed
Summary
This summary is machine-generated.

New therapies for Neuromyelitis Optica Spectrum Disorder (NMOSD) include eculizumab, inebilizumab, satralizumab, and autologous hematopoietic stem cell transplantation (AHSCT). AHSCT may offer the best option for preventing NMOSD progression.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.5K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.1K

Related Experiment Videos

Last Updated: Nov 5, 2025

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.7K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.5K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.1K

Area of Science:

  • Neuroimmunology
  • Autoimmune Disorders
  • Neurology

Background:

  • Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe autoimmune condition causing optic neuritis and transverse myelitis.
  • Many NMOSD patients experience incomplete recovery after relapses, highlighting the need for effective treatments.

Purpose of the Study:

  • To review current and emerging therapeutic options for NMOSD.
  • To compare the mechanisms of action, onset of action, and safety profiles of various NMOSD treatments.
  • To propose a treatment strategy based on the characteristics of each therapy.

Main Methods:

  • Review of indicated agents for NMOSD therapy, including eculizumab, inebilizumab, and satralizumab.
  • Consideration of autologous hematopoietic stem cell transplantation (AHSCT) as a therapeutic option.
  • Analysis of the advantages and drawbacks of each treatment modality.

Main Results:

  • Eculizumab offers immediate efficacy but requires frequent IV administration and is costly.
  • Inebilizumab reduces relapse rates and pathogenic antibody production but may cause immunosuppression.
  • Satralizumab provides immunomodulation with self-administration but has a delayed onset of action.

Conclusions:

  • Autologous hematopoietic stem cell transplantation (AHSCT) may be the optimal therapy for preventing NMOSD progression.
  • A tiered treatment approach is suggested: complement inhibition (eculizumab), immune reconstitution (AHSCT), immunomodulation (satralizumab), and immunosuppression (inebilizumab).
  • AHSCT can also serve as rescue therapy for severe breakthrough NMOSD cases unresponsive to disease-modifying therapies.